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ABSTRACT
The Institute for Quality and Efﬁciency in Health Care (IQWiG) developed—in a consultation process with an international
expert panel—the efﬁciency frontier (EF) approach to satisfy a range of legal requirements for economic evaluation in
Germany’s statutory health insurance system. The EF approach is distinctly different from other health economic
approaches. Here, we evaluate established tools for assessing and communicating parameter uncertainty in terms of their
applicability to the EF approach. Among these are tools that perform the following: (i) graphically display overall
uncertainty within the IQWiG EF (scatter plots, conﬁdence bands, and contour plots) and (ii) communicate the uncertainty
around the reimbursable price. We found that, within the EF approach, most established plots were not always easy to
interpret. Hence, we propose the use of price reimbursement acceptability curves—a modiﬁcation of the well-known cost-
effectiveness acceptability curves. Furthermore, it emerges that the net monetary beneﬁt allows an intuitive interpretation
of parameter uncertainty within the EF approach. This research closes a gap for handling uncertainty in the economic
evaluation approach of the IQWiG methods when using the EF. However, the precise consequences of uncertainty when
determining prices are yet to be deﬁned. © 2014 The Authors. Health Economics published by John Wiley & Sons Ltd.
Received 20 July 2012; Revised 3 January 2014; Accepted 19 January 2014
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1. INTRODUCTION
Health economic evaluation was explicitly introduced to the German Statutory Health Insurance (SHI) system by
the 2007 SHI Competition Reinforcement Act. It required that health economic evaluations should be conducted to
*Correspondence to: IQWiG, Institute for Quality and Efﬁciency in Health Care, Department of Health Economics, Cologne, Germany.
E-mail: stefan.Lhachimi@iqwig.de
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribu-
tion and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
© 2014 The Authors. Health Economics published by John Wiley & Sons Ltd.
HEALTH ECONOMICS
Health Econ. 24: 481–490 (2015)
Published online 4 March 2014 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/hec.3041
set a maximum reimbursable price for pharmaceuticals. Effectively, the SHI—covering ~90% of the German pop-
ulation—would not have to reimburse an amount greater than the maximum reimbursable price for a new drug. To
ensure that the economic evaluation methods conform to a range of legal requirements and constraints—chief
among them: no rationing across indication areas—the German Institute for Quality and Efﬁciency in Health Care
(‘Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen’, IQWiG) developed—in a consultation process
with an international expert panel—the efﬁciency frontier (EF) approach (IQWiG, 2009; Caro et al., 2010).
Currently, the EF approach is applied in all ongoing IQWiG health economic reports. Furthermore, a recent act
(‘Arzneimittelmarktneuordnungsgesetz’—came into effect in 2011) stipulates that, henceforth, either amanufacturer
or the SHI umbrella organization may request the Federal Joint Committee (‘Gemeinsamer Bundesausschuss’)—the
highest decision-making body of the joint self-government of physicians, dentists, hospitals, and SHI funds in
Germany—to commission IQWiG to undertake a health economic evaluation. Such an evaluation must deliver
evidence to establish an appropriate reimbursable price, given a drug’s additional beneﬁt or reduced harm.
The EF approach is distinctly different from other health economic approaches (Brouwer and Rutten, 2010).
So far, it is unclear how to communicate parameter uncertainty that is inherent to every health economic
evaluation within the EF approach to decision-makers. Therefore, the purpose of this report is to evaluate
established tools that are used to communicate the results of a probabilistic sensitivity analysis (PSA) in terms
of their applicability to the EF approach with the help of a simulation. Among these are tools that perform the
following:(i) graphically display overall uncertainty within the IQWiG EF (scatter plots, conﬁdence bands, and
contour plots) and (ii) communicate the uncertainty around the reimbursable price. For the latter, we develop a
price acceptability curve, which is a modiﬁcation of the well-known cost-effectiveness acceptability curve
(CEAC). Furthermore, it emerges that the net monetary beneﬁt (NMB) allows an intuitive interpretation of
parameter uncertainty within the EF approach.
Given the scope of this paper, we do not consider uncertainty with respect to the heterogeneity between (or
across) individual patients or structural uncertainty.
2. BACKGROUND: THE EFFICIENCY FRONTIER APPROACH
The EF approach (Figure 1) aims to provide evidence on an appropriate reimbursable price for treatment
strategies in Germany. Appropriate—as deﬁned in the legal framework of Social Code Book V—means as
compared with other treatment strategies within the same indication area. To construct an EF, all relevant treat-
ment strategies within one indication are plotted on a plane, with costs on the horizontal and health effects on
the vertical axes. All treatment strategies that are not subject to simple or extended dominance are connected in
ascending order of effectiveness (IQWiG, 2009). The resulting curve consists solely of efﬁcient strategies. For
a new treatment strategy under assessment, a reimbursable price must be set such that the associated costs and
effect(s) lie on the linearly extrapolated last segment of the EF. The line extrapolated beyond the last segment of
an EF uses the same trade-off rate for costs and health effects as for the current most effective technology
relative to the second most effective efﬁcient strategy (dashed line in Figure 1). Hence, an increase in effective-
ness is valued by using an observed indication-speciﬁc trade-off between costs and effects.
When calculating the reimbursable price for a new drug, it is important to distinguish between two cost com-
ponents: costs that are affected by the drug price and costs not affected by the drug price. Let π be the price of
the new drug, and let u be the expected number of drug units needed for treatment. For example, more than one
drug application may be needed to cure a patient, and the number of applications may vary across patients; thus,
u  π denotes the average costs deﬁned by the drug price. Let furthermore ecnew denote the costs of the new drug
not related to the drug price; the overall costs cnew of the new treatment strategy can be calculated as follows:
cnew ¼ ec new þ uπ:
If enew denotes the health effect associated with the new treatment strategy and cnewEF denotes the correspond-
ing cost as indicated by the (extrapolated) EF, the reimbursable price can be calculated as follows:
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πmax ¼ c
new
EF  ec new
u
:
If the price π differs from πmax, the NMB can be calculated as follows:
NMB ¼ cnewEF  cnew ¼ cnewEF  ec new  uπ:
Thus, if π = πmax, then NMB=0.
In essence, the EF approach aids policy makers with two crucial tasks: (i) By determining the trade-off
between costs and health effects indicated by the last segment of the EF (Figure 1), the policy makers identify
the existing implicit threshold within an indication and (ii) estimating a reimbursable price for a new drug by
relating this new treatment strategy to already existing treatment strategies.
However, such estimates are subject to parameter uncertainty regarding the input variables, that is, all drug
and non-drug costs and health outcomes. This uncertainty should be communicated to decision-makers.
Notably, the costs do not necessarily correspond to the drug price of the treatment strategies alone, but they also
incorporate use of accompanying services and, depending on the perspective, indirect costs (i.e. costs as a result
of productivity loss (Gold et al., 1996)).
To adequately represent uncertainty within the EF approach, two distinctive yet simultaneously occurring
aspects of uncertainty must be accounted for in each run of a PSA: First, the new treatment strategy may vary
its position on the cost-effectiveness plane, and second, all other treatment strategies may vary their position on
the cost-effectiveness plane as well. Because of the latter, the EF varies its shape, and crucially, the trade-off
between costs and effects as indicated by the last segment of the EF may vary between each run of the PSA.
Figure 1. Illustration of the IQWiG efﬁciency frontier approach. The efﬁcient strategies A, B, and C deﬁne the shape of the efﬁcieny fron-
tier. The dashed line is the extension of the last segment of the efﬁciency frontier (B to C). The horizontal distance between the new inno-
vative strategy and dashed line can be interpreted as the net monetary beneﬁt
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3. SIMULATION STUDY
To illustrate parameter uncertainty within the EF approach, we performed a Monte Carlo simulation. This
simulation corresponds to a PSA in accordance with the approach of Barton et al. (2008); however, we kept
the model assumptions to a minimum. Let k denote the number of strategies already available on the market.
For our simulation study, we assumed the EF to be based on k = ﬁve strategies: three that build the EF, one
strictly dominated strategy and one extendedly dominated strategy. However, because of the Monte Carlo
simulation process, there has been some random variation, that is, which strategies were dominated and which
lay on the EF in each run. A sixth strategy corresponds to the new treatment strategy.
Let ei, i= 1,…, k, be the health effect of the ith strategy already available on the market, and let ci be the
associated costs. As is common in economic evaluations, the costs and the effects among strategies are
correlated; we modelled the joint distribution using the multivariate normal distribution. However, as the costs
of the new treatment strategy depend on the price of the new drug, while at the same time this price needs to be
determined in that same PSA run, both ec new and u were modelled in place of cnew.
We deﬁne y as the vector of health effects and costs of the comparators, non-drug-price-related costs of the
new drug and the number of packages of the new drug (for deﬁnitions refer to the preceding texts):
y ¼ e1;…; ek; enew; c1;…; ck; ec new; uð ÞΤ
and assume
yeN μ;Σð Þ:
Regarding μ and Σ, we assume
μ ¼ 1; 4; 5; 6; 7; 8; 1000; 1400; 1300; 1500; 1600; 1400; 2ð ÞT
with corresponding standard errors:
σy ¼ μ0:06:
Furthermore, we set the correlation matrix P to
P ¼
1 0:7 0:7 0:7 0:7 0:7 0:7 0:6 0:6 0:6 0:6 0:6 0:6
0:7 1 0:7 0:7 0:7 0:7 0:6 0:7 0:6 0:6 0:6 0:6 0:6
0:7 0:7 1 0:7 0:7 0:7 0:6 0:6 0:7 0:6 0:6 0:6 0:6
0:7 0:7 0:7 1 0:7 0:7 0:6 0:6 0:6 0:7 0:6 0:6 0:6
0:7 0:7 0:7 0:7 1 0:7 0:6 0:6 0:6 0:6 0:7 0:6 0:6
0:7 0:7 0:7 0:7 0:7 1 0:6 0:6 0:6 0:6 0:6 0:7 0:7
0:7 0:6 0:6 0:6 0:6 0:6 1 0:8 0:8 0:8 0:8 0:8 0:8
0:6 0:7 0:6 0:6 0:6 0:6 0:8 1 0:8 0:8 0:8 0:8 0:8
0:6 0:6 0:7 0:6 0:6 0:6 0:8 0:8 1 0:8 0:8 0:8 0:8
0:6 0:6 0:6 0:7 0:6 0:6 0:8 0:8 0:8 1 0:8 0:8 0:8
0:6 0:6 0:6 0:6 0:7 0:6 0:8 0:8 0:8 0:8 1 0:8 0:8
0:6 0:6 0:6 0:6 0:6 0:7 0:8 0:8 0:8 0:8 0:8 1 0:8
0:6 0:6 0:6 0:6 0:6 0:7 0:8 0:8 0:8 0:8 0:8 0:8 1
0
BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB@
1
CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCA
:
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This results in the following covariance matrix:
∑ ¼ σyσyΤ
 
⊙P:
The values of the correlation matrix P were chosen for the following reasons: First, the health effect across
the interventions, in general, is positively correlated. This is because of common causal factors, such as
common complementing treatment methods, common background mortality and so on. For simplicity, we
chose only one value (i.e. 0.7) that represents the correlation across the health effect of all interventions.
Second, costs are, in general, positively associated across interventions, as there is a strong overlap of resource
use among strategies. Again, for simplicity, we chose the common value 0.8 for these costs. Third, for a given
strategy, the health effects and the costs are, in general, correlated. This correlation may be either positive or
negative. A positive correlation would be, for example, because of additional resource consumption in life
years gained; a negative correlation would be, for example, because of less resource consumption in cured
subjects. We decided to choose a negative value (i.e. 0.7), for reasons of visual clarity when displaying the
scatter plot. However, note that this is an arbitrary choice. Finally, the correlation between costs and effects
of alternative strategies had to be deﬁned. Because of the already speciﬁed correlations described previously,
the choice of these values has been limited. For example, as costs across interventions were positively
correlated, effects across interventions were also positively correlated, but costs and effects within one
intervention were negatively correlated; hence, the correlation between costs and effects of alternative
strategies had to be negative as well. Furthermore, the numerical values selected previously restricted the
choice of values of the correlation between costs and effects of alternative strategies. Otherwise, the Cholesky
decomposition of the covariance matrix would not be deﬁned, which has to be determined within the process of
simulating multivariate normally distributed values (Briggs et al., 2006; Stollenwerk et al., 2010). Thus, we
chose the value 0.6, which was consistent with the previously chosen values.
The number of runs used for PSA was 1000. For each run of the PSA, the EF approach was applied.
3.1. Displaying uncertainty on the cost-effectiveness plane
The shape of the EF can be highly sensitive to parameter uncertainty. Traditional scatter plots are not suitable to
display the uncertainty of the shape of an EF (Figure 2, illustration based on the simulation study), as they do
not yield information about which dots belong to the common runs of the PSA. This problem can be overcome
via conﬁdence bands (Figure 3) or contour plots (Figure 4). Conﬁdence bands can be constructed pointwise
(Appendix). However, these are only deﬁned over the range for which all PSA-based EFs are also deﬁned.
Contour plots, instead, are deﬁned over the whole cost-effectiveness plane (refer to Appendix on construction
of contour plots). Even though contour plots may appear to display the uncertainty about the shape of the EF
reasonably well, neither contour plots nor conﬁdence bands give information about the uncertainty of the
reimbursable price, which—as explained above—is the intended output of the EF approach.
3.2. Expressing uncertainty around the reimbursable price
Conﬁdence intervals are problematic when applied to incremental cost-effectiveness ratios, as costs and effects
can fall into more than one quadrant for the cost-effectiveness plane (Briggs, 2001; Briggs et al., 2006). CEACs
were developed in response to these problems and provide an elegant solution. These report, for a range of
willingness-to-pay threshold values, the probability that the intervention’s cost-effectiveness is acceptable.
This, however, only relates whether the incremental effects justify the incremental costs in a yes-or-no decision
for a given threshold.
We introduce price acceptability curves (PACs). They are analogous to the CEAC; however, the horizontal
axis here refers to the price of the new drug. The vertical axis still corresponds to the probability that the
innovative strategy is ‘cost effective’. Thus, for each price, it is counted, which percentage of the simulated
maximum reimbursable prices is above or on the EF (Figure 5).
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Price acceptability curves can be constructed as follows: Within each run of the PSA, the EF approach is
applied and the threshold, as determined by the last segment of the EF, is identiﬁed. This yields a
reimbursable price for each run. Now, for every possible price (x-axis), the PAC illustrates the percentage
of the simulation runs where the reimbursable price is equal or below a maximum reimbursable price, that
is, the price on the x-axis.
Another way of displaying the uncertainty around the reimbursable price in the context of the EF is using the
NMB framework. Within the EF, the NMB has an intuitive graphical interpretation. As can be seen in Figure 1,
the NMB is the horizontal distance between the new treatment strategy and the last segment of the EF. The
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Figure 2. Scatter plot of strategies on the cost-effectiveness plane, based on probabilistic sensitivity analysis
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Figure 3. Pointwise 95% conﬁdence band of efﬁciency frontier for given costs; the pointwise conﬁdence band is only deﬁned over the
range for which all efﬁciency frontiers are deﬁned
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distance indicates by how much the price must be increased or lowered to be positioned on the EF. The NMBs
for each run of the PSA can be calculated and ordered according to the size of NMB from the highest negative
to highest positive values. The NMB can be plotted as a function of the price (Figure 6). The vertical axis shows
the price π, and the horizontal axis shows, for a given price, the expected NMB over all PSA results.
Additionally, the conﬁdence intervals or percentiles of the NMB distribution can be added, yielding a corridor
expressing the uncertainty for the decision-maker. Without loss of generality, using the NHB instead of the
NMB yields identical conclusions. In this case, the horizontal distance between the new treatment strategy
and EF is calculated.
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Figure 4. Contour plot of efﬁciency frontier; the grid was deﬁned as 10 evenly spaced threshold values ranging from the minimum to the
maximum of the simulated values for each axis (refer to Appendix for details)
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Figure 5. Price acceptability curve based on the IQWiG efﬁciency frontier approach
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4. DISCUSSION
In this paper, we evaluated tools used for the assessment and visual communication of parameter uncertainty in
the EF approach. We have discussed scatter plots, conﬁdence bands, and contour plots to display overall
parameter uncertainty and developed the PAC, that is, a modiﬁcation of the CEAC. Furthermore, we presented
an approach of displaying the NMB, which has an intuitive interpretation when using the EF approach, as a
function of the price.
The dual aim of the EF—(i) establishing the threshold for a given indication and (ii) deriving a recommen-
dation for the reimbursable price of a new treatment strategy—poses a challenge to the traditionally used
approaches that build upon a ﬁxed threshold. Therefore, a new aspect of our research question is that the
threshold may be regarded as probabilistic and that a probability distribution of a maximum reimbursable price
can be derived. This may be relevant also for the non-German context and for approaches where the threshold is
estimated based on methods other than the EF approach. For example, in the literature, it has previously been
discussed to estimate the threshold as willingness to pay based on population surveys (Hirth et al., 2000; Ryan
et al., 2004). However, also these estimates would be uncertain and should be varied within PSA. Furthermore,
given the current debate around value-based pricing, the goal of health economic evaluation might not be a yes-
or-no reimbursement decision any longer but rather a price estimate for the new drug. Moreover, uncertainty
around such a price estimate needs to be made transparent for decision-makers, that is, to know how wide
the corridor of a reliable and valid price estimate could be.
Nevertheless, depicting uncertainty in the aforementioned way entails further open questions: (i) How
should the reported uncertainty be interpreted and used to guide decision-making regarding a reimbursable
price and (ii) on which percentile would one deliver a reasonable interval or corridor?
(i) One option would be to neglect parameter uncertainty when determining a reimbursable price by sticking
to the point estimate of the base case analysis. However, some decision-makers might be tempted to apply
uncertainty intervals around the reimbursable price in a similar way as conﬁdence intervals when performing
statistical tests. In a simple case, one would assume a symmetric distribution of the price with a two-sided
hypothesis. At a 5% ‘signiﬁcance level’, either the 2.5th or the 97.5th percentile could be applied. A very con-
servative approach would be to require that the 2.5th percentile would have to be at least on or above the EF. In
this scenario, the manufacturer of a new drug would be punished given a high level of uncertainty. Should the
decision-maker regard a price as appropriate, if the NHB is not ‘signiﬁcantly’ below zero, this would be much
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Figure 6. Net monetary beneﬁt based on the IQWiG efﬁciency frontier approach
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laxer for the manufacturer. Based on this rationale, the 97.5th percentile of all simulated reimbursable price
estimates would serve as the reimbursable price. Thus, manufacturers would, in contrast to the ﬁrst approach,
be rewarded for parameter uncertainty. Given that distributions do not necessarily have to be symmetric, this
approach would not be feasible.
(ii) The originally published IQWiG concept did not reﬂect the depiction of uncertainty when determining a
reimbursable price (IQWiG, 2009). As the law stipulates that an appropriate price—in relation to other treat-
ment strategies—must be set, one could say that the traditional 95% conﬁdence interval would not serve this
purpose. Therefore, IQWiG proposed to additionally display the 25% and 75% percentile, that is, interquartile
range, as a reasonable ‘corridor of uncertainty’ and acceptable for both stakeholders, SHI funds and pharmaceu-
tical manufacturers. As the width of the corridor/interval could heavily inﬂuence the decision to be taken, it
needs to be chosen carefully. At present, we suggest that both questions need to be thoroughly debated by
decision-makers and health economic experts in order to identify an answer.
Another conclusion that could be drawn from high uncertainty is that better evidence needs to be generated.
However, the PACs report no information regarding to what extent each parameter is responsible for the
resulting uncertainty. The contribution of each model parameter to the overall uncertainty could, for example,
be detected via analysis of covariance (ANCOVA) (Briggs et al., 2006). The ANCOVA approach assumes a
linear relationship between the parameter and the target variable (here, the price). Another approach for
assessing the value of further data collection is based on estimating the contribution of each parameter to the
expected value of perfect information (Claxton, 1999).
While we focused on quantifying and depicting parameter uncertainty when determining a reimbursable
price with the IQWiG EF approach, we, the authors, are aware that there is an ongoing debate on the
implications of the IQWiG EF approach (Schwarzbach et al., 2009; Dintsios and Gerber, 2010; Greiner
et al., 2010; Sculpher and Claxton, 2010; Gandjour, 2011). Nevertheless, this was not the subject of this paper
and hence has not been addressed.
5. CONCLUSION
In conclusion, we derived a method of presenting the degree of parameter uncertainty on the reimbursable price
within the EF approach. By doing so, we closed a gap within the EF approach. Furthermore, our research may
be useful to present the uncertainty of the appropriate reimbursable price, if concepts other than the EF
approach are applied to deﬁne or estimate the threshold. This may also be helpful outside the German context,
as future decisions may more frequently not be simple dichotomous yes-or-no reimbursement decisions but
decisions based on a recommended price for a given beneﬁt. However, further research regarding the EF
approach and regarding how to determine reimbursable prices is needed.
APPENDIX
Pointwise conﬁdence bands can be estimated based on the single EFs that result from PSA. For given costs,
95% conﬁdence intervals can be derived by calculating the 2.5% and the 97.5% quantile of the corresponding
health effect. For our illustration, we calculated 95% conﬁdence intervals for a sequence of 10 uniquely spaced
cost values. Conﬁdence bands were approximated via piecewise linear interpolation.
To calculate contour plots, a grid has to be deﬁned for both costs and the health effects. For each cell within
this grid, the runs of the PSA and their crossings by the EF are counted. Each crossing is referred to as a hit. The
share of hits is furthermore linked to the middle of one cell, and the general methodology of calculating contour
plots is applied (Cleveland, 1993). This is done by creating approximate contours based on interpolating the
points over the grid (Cleveland, 1993). In interpreting the contour plots, however, one has to keep in mind that
the expected number of hits depends on the widths chosen for the grid: The ﬁner the grid, the lower the
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expected number of hits. We deﬁned the grid as 10 evenly spaced threshold values ranging from the minimum
to the maximum of the simulated values for each axis.
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